The Canadian Medical Isotope Ecosystem, which is backed by the Canadian federal government’s Strategic Innovation Fund, has announced funding for a collaboration between Promation, Astral Systems, and McMaster University to establish a proof-of-concept approach for a fusion reaction–based copper-67 production process with automated postirradiation isotope separation and purification.

Australia-based Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, has signed a supply agreement for copper-67 with Nusano, Inc., headquartered in California. Nusano produces radioisotopes for medical, commercial, and industrial applications.